Table S1 Types and timing of infections

Clinical variable	Infection in 30–90 days	Infection 90 days–6 months	Infection 6 months–1 year	Infection 1–2 years
Type of Infection (patient)	bacterial (n=3), viral (n=3)	bacterial (n=1), viral (n=2), fungal (n=3)	bacterial (n=1), viral (n=2), fungal (n=1)	viral (n=4), bacterial (n=2)
Location (patient)	respiratory (n=2), lower GI (n=1), eye (n=1), blood (n=2), GU (n=1)	respiratory (n=3), CSF (n=1), blood (n=2), oropharynx (n=1), GU (n=1)	respiratory (n=5), blood (n=1)	respiratory (n=4), GU (n=1)
Organism (patient)	Bacterial pneumonia NOI (n=1)*, C difficile colitis (n=1), HSV keratitis (n=1)*, Rhinovirus (n=1), VRE UTI(n=1), CMV viremia (n=2)	Cryptococcal meningitis (n=1)*, CMV viremia (n=1)*, pseudomonas bacteremia (n=1) *, BK virus in urine (n=1)*, Oral candidiasis (n=1), COVID-19 (n=1), Fungal pneumonia (n=by fungitell) (n=1)	Influenza A (n=2)*, Bacterial pneumonia NOI (n=1)*, Parainfluenza (n=1)*; Disseminated Cryptococcosis (n=1)*, COVID-19 (n=1),	RSV (n=1), Influenza A H1N1 (n=1), E. coli UTI (n=1), COVID-19 (n=1)*, Pseudomonas pneumonia* (n=1)

*, Patient with HIV on ART. GU, genitourinary; CSF, cerebrospinal fluid; NOI, no organism identified; C. difficile, clostridium difficile; VRE, vancomycin-resistant enterococcus; UTI, urinary tract infection; CMV, cytomegalovirus; COVID-19, coronavirus disease 19; RSV, respiratory syncytial virus

Table S2 Prevalence of cytopenia after CAR-T cell therapy.

Cytopenia	D30–90 (n=19)	D90–180 (n=14v	D180–1 year (n=11)	1–2 years (n=5)
Neutropenia, n [%]				
Normal (≥1,500/µL)	5 [26]	7 [50]	6 [55]	1 [20]
Mild (<1,500/µL)	5 [26]	1 [7]	4 [36]	1 [20]
Moderate (<1,000/µL)	8 [42]	5 [36]	0 [0]	1 [20]
Severe (<500/µL)	1 [5]	1 [7]	1 [9]	2 [40]
Lymphopenia, n [%]				
Normal (≥1,000/µL)	3 [16]	4 [29]	5 [45]	1 [20]
Mild (<800/µL)	5 [26]	0 [0]	1 [9]	2 [40]
Moderate (<600/µL)	6 [32]	6 [42]	3 [27]	0 [0]
Severe (<200/µL)	2 [11]	1 [7]	1 [9]	2 [40]
Thrombocytopenia, n [%]				
Normal (≥150/ µL)	1 [5]	3 [21]	3 [27]	0 [0]
Mild (<75,000/µL)	2 [11]	2 [14]	0 [0]	1 [20]
Moderate (<50,000/µL)	3 [16]	1 [7]	0 [0]	0 [0]
Severe (<25,000/µL)	4 [21]	1 [7]	1 [9]	2 [40]
Use of G-CSF beyond D30, n [%]	7 [37]	4 [29]	1 [9]	1 [20]

n=patients with data available during the specified time period.

Table S3 Summary of CAR-T cell toxicities and their management

CAR-T cell toxicity and management	Number of patients	Percentage
CRS	12	63
Grade 1	8	42
Grade 2	3	16
Grade 3	1	5
ICANS	14	74
Grade 1	8	42
Grade 2	3	16
Grade 3	2	11
Grade 4	1	5
Neutropenic fever	14	74
Use of tocilizumab	6	32
Use of steroids	3	16